EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center

Angela Ayén-Rodríguez iD, Laura Linares-González, Carlos Llamas-Segura, Francisco Manuel Almazán-Fernández, Ricardo Ruiz-Villaverde iD

International Journal of Environmental Research and Public Health · 2023

DOI: 10.3390/ijerph20105824 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Angela Ayén-Rodríguez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain. Hauptthemen laut MEDLINE: Skin Neoplasms, Antineoplastic Agents, Basal Cell Carcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Basal cell carcinoma (BCC) is the most common type of skin cancer and can represent a therapeutic challenge in patients with locally advanced disease. Vismodegib is a hedgehog pathway inhibitor approved by the FDA for use in this type of tumor. We present a case series to describe our experience with the use of vismodegib.

Methods

A retrospective study that included patients treated with vismodegib at our dermatology unit was conducted. Monthly follow-up was performed, and we registered the clinical evolution and adverse reactions.

Results

A total of six patients with locally advanced BCCs were included (50% males and 50% females), with a mean age of 78.5 years old. The treatment was administered over a mean of 5 months. A complete response was observed in four cases and partial response in two cases. No recurrence was detected, with a median follow-up duration after discontinuation of 18 months. Most patients (83%) had at least one adverse event, and two needed dose adjustment temporarily or permanently to continue. The main adverse effect was muscle spasms (66.7%). The main limitation of our study was the small sample, which was not representative of the general population.

Conclusions

Vismodegib is a safe and effective treatment for locally advanced BCC, and its role in unresectable BCC seems to be an important option in these challenging cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsAntineoplastic AgentsBasal Cell CarcinomaMaleRetrospective StudiesHedgehog ProteinsFemaleHumansAgedAnilidesPyridinesHamartoma Syndrome, Multiple

Stichwörter der Autor:innen

hedgehog inhibitorlocally advanced basal cell carcinomanonmelanoma skin cancervismodegib

Substanzen

Hedgehog ProteinsAntineoplastic AgentsHhAntag691AnilidesPyridines

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, Spain.

ORCID-Profile: Angela Ayén-Rodríguez, Ricardo Ruiz-Villaverde

Zitieren

APA

Ayén-Rodríguez, A., Linares-González, L., Llamas-Segura, C., Almazán-Fernández, F. M., & Ruiz-Villaverde, R. (2023). Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20105824

Vancouver

Ayén-Rodríguez A, Linares-González L, Llamas-Segura C, Almazán-Fernández FM, Ruiz-Villaverde R. Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20105824

BibTeX
@article{AynRodrguez2023,
  author = {Ayén-Rodríguez, Angela and Linares-González, Laura and Llamas-Segura, Carlos and Almazán-Fernández, Francisco Manuel and Ruiz-Villaverde, Ricardo},
  title = {Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center},
  journal = {International Journal of Environmental Research and Public Health},
  year = {2023},
  doi = {10.3390/ijerph20105824}
}
Kostenlos starten →